Your World of Legal Intelligence
 United Kingdom | +44 (0) 20 7284 8080

Centene to Divest Two Pharmacy Businesses for USD 2.8bn Upfront.

Document Cited in Related
Vincent

MANews-(C)2009-2022

US-based health insurer Centene Corp. (NYSE: CNC) has signed a definitive agreement to sell its Magellan Rx pharmacy solutions organization to Prime Therapeutics LLC and a separate definitive agreement to sell its PantheRx Rare specialty and rare pharmacies business to a consortium of The Vistria Group, General Atlantic, and Nautic Partners, the company said.

Subject to customary purchase price adjustments, Centene expects to receive aggregate proceeds of approximately USD 2.8 bn from the transactions.

Magellan Rx is a pharmacy solutions organization with leading capabilities in specialty drug management, Medicaid administration, and comprehensive pharmacy benefits management.

Centene acquired Magellan Rx in January 2022 as part of its acquisition of Magellan Health, Inc.

The sale of Magellan Rx is subject to US federal antitrust clearance, receipt of applicable regulatory approvals and satisfaction of other customary closing conditions and is expected to close in 4Q22.

In the sale of Magellan Rx, Allen and Company LLC and Evercore are serving as financial advisors to Centene, and Skadden, Arps, Slate, Meagher and Flom LLP is serving as its legal counsel.

Solomon Partners is serving as exclusive financial advisor and placement agent to Prime and McDermott Will and Emery and Fox Rothschild LLP are serving as its legal counsel.

PantheRx is one of the largest and fastest growing specialty and rare pharmacies in the United States.

Centene acquired PantheRx in December 2020. The sale of PantheRx is...

To continue reading

Request your trial
COPYRIGHT Normans Media Ltd.

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT